Dermagen Reports Successful Phase I/IIa Clinical Trial For Atopic Dermatitis

DermaGen ABpart of the Karolinska Development dermatology and wound healing company “Pergamum” announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis…

source : www.medicalnewstoday.com

Related News:

• ACT Files Documentation With FDA For Clinical Trials Using ES Cells To Treat Eye Disease
• Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
• Orthovita Announces Presentations Of Cortoss Clinical Study Results At The 17th International Meeting Of Advanced Spine Technologies
• Vitamin A Deficiency In New York City
• BSD Medical Announces Presentation At ASCO Of Duke University Clinical Study Using Hyperthermia With Chemotherapy To Treat Bladder Cancer
• News From The Journal Of Clinical Investigation: July 12, 2010
• Rubicon Genomics’ PicoPlex™ Linear Amplification Technology Enables Successful International Clinical Genetic Study Of Single Human Cells
• PROLOR Biotech Granted EU GMP Certification For Lead Candidate HGH-CTP, A Pre-Condition For Its Phase II Clinical Trial
• A New Forum For Basic And Translational Research, Showcasing Cutting-Edge New Research By Pre-Clinical Scientists
• Molecular Insight Pharmaceuticals Presents Positive Data From AzedraTM Phase 2a Clinical Trial In Neuroblastoma Tumors

Details :
Submited at Monday, December 7th, 2009 at 1:00 am on Dermatology by jessica
Comment RSS 2.0 - leave a comment - trackback